EUCTR2020-000883-42-FR进行中（未招募）1 期
Impact of omalizumab withdrawal after a 3 year duration treatment in well controlled severe allergic asthma : a multicentric randomized controlled trial
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 234
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 234
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 234
排除标准
- 未提供
研究者
相似试验
招募中
4 期
Short Treatment with Omalizumab for Severe AsthmaAsthmaNCT04763447Assistance Publique - Hôpitaux de Paris234
已完成
不适用
Clinical effects of treatment with omalizumab in patients with asthmaBronchial asthmaJPRN-UMIN000002765Atami Hospital International University of Health and Welfare40
已完成
不适用
Impact of Adalimumab Withdrawal or Continuation on Severity of COVID-19 and Risk of IMID RelapseInflammatory Bowel DiseasesRheumatic DisorderNCT05706038IRCCS San Raffaele49
招募中
1 期
Extending omalizumab treatment intervals in patients with chronic spontaneous urticaria (EXOTIC trial)Chronic spontaneous urticariaCTIS2023-506187-14-00Bispebjerg Hospital40
已完成
不适用
Discontinuation of adalimumab without functional and structural damage progression after attaining sustained remission in patients with rheumatoid arthritis: An observational studyRheumatoid ArthritisJPRN-UMIN000006669niversity of Occupational and Environmental Health, Japan50